Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 1999

View Archived Issues

Incyte and Schering expand agreement

Aventis R&T expands drug discovery collaboration with Nanogen

NeoTherapeutics initiates phase II trial to study effects of Neotrofin on the brain

Pharming awarded grants for human lactoferrin research; announces collaboration

ASBMR participants learn of efficacy, safety of risedronate in several large studies

FDA approves Rochester Medical's FemSoft Insert for female stress urinary incontinence

DuPont, Janssen and Neurocrine Biosciences establish CRF collaboration

Integrin antagonist S-787 prevents ovariectomy-induced bone loss in rats

SmithKline Beecham reports advances in vitronectin receptor antagonist research

Adenosine-dependent cardioprotective effect demonstrated for MX-68

SUN-N4057 reduces both brain and body temperature in cat model of stroke

Preparation and use of dual ETA/ETB antagonists disclosed by BASF

Plant-produced antiangiogenic compound discovered by Phytera

New CRF antagonists codeveloped by Janssen and Neurocrine Biosciences

Novel monoamine reuptake inhibitors designed at ADIR, particularly useful in depression

Novo Nordisk investigates new strategy for diabetes and its complications: normoglycemic agents

Lilly and Synaptic investigate potential of 5-HT1A antagonist in nicotine withdrawal

Nitrate salts of antiulcer agents exhibit improved pharmacological, toxicological profile

Bayer's IL-4 antagonist for asthma enters clinical testing

Potent phenylisoxazoline antimicrobial agents designed at Pharmacia & Upjohn

Scotia seeks approval of Foscan in Europe

Roche confirms AD drug dropped by the wayside; two other MAO-B inhibitors remain in development

Lipopeptide synthesized at Abbott may be therapeutically useful antifungal agent

New class of oxazolidinones with broader spectrum presented at ICAAC by Pharmacia & Upjohn

Bacterial efflux pump inhibitors developed at Microcide and presented at ICAAC meeting

CuraGen and Glaxo Wellcome complete Alzheimer's disease research program

Meiji Seika issues updated product pipeline

rhPM-1 inhibits synovial cell proliferation in vitro, inflammatory cell infiltration in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...